EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Untargeted Metabolomics Identifies Potential Hypertrophic Cardiomyopathy Biomarkers in Carriers of MYBPC3 Founder Variants

Mark Jansen iD, Maike Schuldt iD, Beau O van Driel iD, Amand F Schmidt, Imke Christiaans, Saskia N van der Crabben, Yvonne M Hoedemaekers, Dennis Dooijes, Jan D H Jongbloed iD, Ludolf G Boven, Ronald H Lekanne Deprez iD, Arthur A M Wilde und 6 weitere

International Journal of Molecular Sciences · 17.02.2023 · 24 (4) · 4031

DOI: 10.3390/ijms24044031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.02.2023. Verfasst von Mark Jansen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, University Medical Centre Utrecht, Utrecht University, 3584CX Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Myosins, Founder Effect. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Netherlands Organisation for Health Research and Development, Hartstichting, UCL Hospitals NIHR Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypertrophic cardiomyopathy (HCM) is the most prevalent monogenic heart disease, commonly caused by pathogenic MYBPC3 variants, and a significant cause of sudden cardiac death. Severity is highly variable, with incomplete penetrance among genotype-positive family members. Previous studies demonstrated metabolic changes in HCM. We aimed to identify metabolite profiles associated with disease severity in carriers of MYBPC3 founder variants using direct-infusion high-resolution mass spectrometry in plasma of 30 carriers with a severe phenotype (maximum wall thickness ≥20 mm, septal reduction therapy, congestive heart failure, left ventricular ejection fraction

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicMyosinsFounder EffectHumansBiomarkersCase-Control StudiesCytoskeletal ProteinsMutationPhenotypeStroke VolumeVentricular Function, LeftHeterozygoteMaleMyosin Binding Protein C

Stichwörter der Autor:innen

MYBPC3biomarkershypertrophic cardiomyopathymetabolomics

Substanzen

BiomarkersCytoskeletal ProteinsMyosinsMyosin Binding Protein C

Autor:innen und Institutionen

  • Department of Genetics, University Medical Centre Utrecht, Utrecht University, 3584CX Utrecht, The Netherlands.
  • Netherlands Heart Institute, 3511EP Utrecht, The Netherlands.
  • Department of Physiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, 1081HZ Amsterdam, The Netherlands.
  • Department of Cardiology, University Medical Centre Utrecht, Utrecht University, 3584CX Utrecht, The Netherlands.
  • Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, London WC1E 6DD, UK.
  • Department of Genetics, University Medical Centre Groningen, University of Groningen, 9713GZ Groningen, The Netherlands.

ORCID-Profile: Mark Jansen, Maike Schuldt, Beau O van Driel, Jan D H Jongbloed, Ronald H Lekanne Deprez, Judith J M Jans, Jolanda van der Velden, J Peter van Tintelen, Folkert W Asselbergs

Förderung

  • Netherlands Organisation for Health Research and Development
  • Hartstichting
  • UCL Hospitals NIHR Biomedical Research Centre
  • Netherlands Cardiovascular Research Initiative: An initiative with the support of the Dutch Heart Foundation
  • Dutch Heart Foundation
  • Dutch Research Council (NWO)-ZonMW
  • ZonMW and Heart Foundation for the translational research program

Zitieren

APA

Jansen, M., Schuldt, M., van Driel, B. O., Schmidt, A. F., Christiaans, I., van der Crabben, S. N., Hoedemaekers, Y. M., Dooijes, D., Jongbloed, J. D. H., Boven, L. G., Deprez, R. H. L., Wilde, A. A. M., Jans, J. J. M., van der Velden, J., de Boer, R. A., van Tintelen, J. P., Asselbergs, F. W., & Baas, A. F. (2023). Untargeted Metabolomics Identifies Potential Hypertrophic Cardiomyopathy Biomarkers in Carriers of MYBPC3 Founder Variants. International Journal of Molecular Sciences, 24(4), 4031. https://doi.org/10.3390/ijms24044031

Vancouver

Jansen M, Schuldt M, van Driel BO, Schmidt AF, Christiaans I, van der Crabben SN, et al. Untargeted Metabolomics Identifies Potential Hypertrophic Cardiomyopathy Biomarkers in Carriers of MYBPC3 Founder Variants. International Journal of Molecular Sciences. 2023;24(4):4031. doi:10.3390/ijms24044031

BibTeX
@article{Jansen2023,
  author = {Jansen, Mark and Schuldt, Maike and van Driel, Beau O and Schmidt, Amand F and Christiaans, Imke and van der Crabben, Saskia N and Hoedemaekers, Yvonne M and Dooijes, Dennis and Jongbloed, Jan D H and Boven, Ludolf G and Deprez, Ronald H Lekanne and Wilde, Arthur A M and Jans, Judith J M and van der Velden, Jolanda and de Boer, Rudolf A and van Tintelen, J Peter and Asselbergs, Folkert W and Baas, Annette F},
  title = {Untargeted Metabolomics Identifies Potential Hypertrophic Cardiomyopathy Biomarkers in Carriers of MYBPC3 Founder Variants},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {4},
  pages = {4031},
  doi = {10.3390/ijms24044031}
}
Kostenlos starten →